None of the data in this trial is "useless" (your word not mine). I believe PFS will finally be able to be effectively measured and correlated to OS by the end of this trial and OS benefit leads to approval sooner than later. I think regulators will eventually adopt measures used in this trial for future trials which will lead to shortened trials and reduced discovery costs for immunotherapy trials. Best wishes.
Market Data 
Markets 
AI
